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Summary 
The secretion of insulin is controlled by the rate of 
glucose metabolism in the pancreatic p cells. As phos- 
phorylation by glucokinase (GLK) appears to be the 
rate-limiting step for glucose catabolism in p cells, this 
enzyme may be the glucose sensor. To test this possi- 
bility and to resolve the relative roles of liver and fl cell 
GLK in maintaining glucose levels, we have generated 
mice completely deficient in GLK and transgenic mice 
in which GLK is expressed only in p cells. In mice with 
only one GLK allele, blood glucose levels are elevated 
and insulin secretion is reduced. GLK-deficient mice 
die perinatally with severe hyperglycemia. Expression 
of GLK in p cells in the absence of expression in the 
liver is sufficient for survival. These mice demonstrate 
the critical need for p cell GLK in maintaining normal 
glucose levels and provide a novel model for one form 
of noninsulin-dependent diabetes. 
Introduction 
Because both hyper- and hypoglycemia can have signifi- 
cant health consequences, the circulating level of glucose 
in humans is normally tightly regulated. Insulin, the princi- 
pal regulator of serum glucose concentrations, is released 
by the pancreatic p cells in response to an increase in 
glucose, inhibits glucose production by the liver, and stim- 
ulates glucose uptake into muscle and fat. Diabetes melli- 
tus results from either a failure to produce sufficient insulin 
or an impairment in the response to insulin. 
Understanding how the 0 cells sense an alteration in 
glucose levels is critical to understanding how glucose 
homeostasis is maintained. Glucose sensing is mediated 
through an increase in the rate of intracellular catabolism 
of glucose rather than a ligand-receptor interaction (Grod- 
sky et al., 1963; Coore and Randle, 1964; reviewed by 
Cook and Taborsky, 1990). However,  it is likely that there 
is still a need for a rate-limiting step in glucose catabolism 
to serve the role of glucose sensor. A compelling case 
has been made for glucokinase (GLK) fulfilling this role 
(reviewed by Matschinsky et al., 1993). 
GLK is one member of the hexokinase family (reviewed 
by Cornish-Bowden and Cardenas, 1991). It has a high 
substrate specificity for glucose and has a relatively high 
K, of about 10 mM (versus 0.1-0.001 mM for the other 
hexokinases). The enzyme has a sigmoidal glucose de- 
pendency with an inflection point around the physiological 
glucose concentration (5 mM glucose). Furthermore, the 
rate of glucose phosphorylation appears to be significantly 
less than the rate of glucose entry into the p cells via 
GLUT2, the b cell-liver glucose transporter (Tal et al., 
1992; Liang et al., 1994). These characteristics are consis- 
tent with the possibility that GLK is the main glucose sen- 
sor in the p cell (reviewed by Mueckler, 1993; Matschinsky 
et al., 1993). 
The genetic analysis of a relatively mild form of noninsu- 
l in-dependent diabetes mellitus (NIDDM) known as matu- 
rity onset diabetes of the young (MODY) also suggests that 
GLK is the primary glucose sensor in the p cells. MODY is 
inherited as a single dominant mutation. In about 50% of 
patients, MODY is associated with mutations in the gene 
encoding GLK(Hattersleyet al., 1992; Froguel et al., 1993; 
Vionnet et al., 1992; Katagiri et al., 1992; Sun et al., 1993; 
Velho et al., 1992). These mutations result in altered GLK 
activity when the appropriate Escherichia coli derived 
forms are analyzed (Takeda et al., 1993; GidhJain et al., 
1993). GLK mutations have also been reported in a subset 
of patients with gestational diabetes (Stoffel et al., 1993) 
and in a small number of Japanese NIDDM patients (Ka- 
tagiri et al., 1992). There are no reports of individuals who 
completely lack GLK. 
Functional GLK protein appears to be made mainly in 
the pancreatic p cells and in liver. A GLK-like protein may 
also be produced in jejunal enterocytes, the pituitary, and 
the medial hypothalamus (Jetton et al., 1994). In the liver, 
GLK may participate in the regulation of glucose uptake 
or output by maintaining a concentration gradient for glu- 
cose. The role of GLK in the other t issues is unclear. Both 
the rat (Magnuson and Shelton, 1989) and the human (Ko- 
ranyi et al., 1992) GLK genes are transcribed using two 
different promoters. The resulting transcripts differ only 
in their S/ends, leading to two proteins with different N-ter- 
mini. The liver-specific promoter is induced by insulin (Mag- 
nuson et al., 1989). The other promoter is used in fi cells 
(and possibly other tissues). Transcription in p cells does 
not appearto be regulated by insulin; instead, GLK activity 
seems to be controlled on a translational or posttransla- 
tional basis according to glucose levels (Bedoya et al., 
1986; Liang et al., 1992; reviewed by Magnuson, 1992). 
Some aspects of the role of GLK in glucose homeostasis 
have been addressed by performing whole-body analysis 
on patients with MODY. However,  there are several signifi- 
cant questions that would be difficult to address in human 
patients but could be approached by a combination of 
gene knockouts and transgenes in mouse models. First, 
what are the consequences of a complete lack of GLK? 
It is possible that alternate enzymes (the hexokinases) can 
be up-regulated and compensate for the absence of GLK. 
Second, how much of the hyperglycemia in MODY pa- 
tients is caused by a reduction in liver as compared with 
fi cell GLK activity? Third, as glucose stimulates transcrip- 
tion of the insulin gene and translation of the insulin mRNA, 
does the level of GLK affect these activities? Fourth, what 
effect would an absence of GLK have on the other t issues 
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(enterocytes, brain, and pituitary) that are known to be 
glucose responsive? 
We have used a combination of gene inactivation and 
transgenic strategies to produce mice that have either one 
normal and one inactive GLK allele, two inactive GLK al- 
leles, or expression of a 8 cell-specific GLK transgene 
but no functional GLK in any of the other tissues. Mice 
with one functional GLK allele develop a mild diabetes, 
comparable to that seen in the MODY patients, and mice 
completely deficient in GLK are extremely diabetic and 
die approximately 5 days after birth (P5). Expression of 
GLK in 6 cells in the absence of GLK in the liver is sufficient 
for survival and, at least in some mice, to maintain near 
normal glucose levels. 
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Generation of GLK Knockout and Transgenic Mice 
The mouse GLK gene was inactivated by the replacement 
of all of exon 4 and parts of exons 3 and 5 by a neomycin 
(neo) resistance gene. From previous characterizations of 
GLK mutants (see Discussion), it was anticipated that this 
deletion in the mouse GLK gene would prevent the synthe- 
sis of an active GLK protein. This assumption was borne 
out by analysis of the mice carrying this mutation (see 
below). The targeting vector is diagrammed in Figure 1, 
and details of the construction are given in Experimental 
Procedures. Two independent embryonic stem (ES) cell 
lines transmitted the mutation and gave rise to two GLK- 
deficient mouse lines (GLKa and GLKb). The founder mice 
were bred to either C57BL16J or DBA12J mice to generate 
mice that are heterozygous for the mutation, hereafter re- 
ferred to as GLK (+I-) mice. Intercrosses between GLK 
(+I-) mice yielded GLK (-I-) mutants. The wild type, het- 
erozygotes, and the homozygotes were born with the ex- 
pected 1:2:1 ratio, but GLK (-I-) mice died at postnatal 
days 3-5 (P3-P5). These mice are markedly diabetic (see 
below), which could account for the mortality. Alterna- 
tively, as these mice appear to stop feeding at around P3, 
they could be dying from starvation. 
Figure 1. Targeting of the GLK Gene and 8 Cell GLK Transgene Con- 
struct 
The principal sites of expression of GLK are the 6 cells 
and the liver. Both organs are critically involved in glucose 
homeostasis. Thus, we anticipated that interpretation of 
the GLK deletion results would be aided by having mice 
that expressed GLK in the 6 cells but were GLK deficient 
in all of the other tissues. To accomplish this, we gener- 
ated transgenic mice carrying the 8 cell GLK cDNA iso- 
form under the control of the human insulin promoter 
plNS.GLK.HBS (see Experimental Procedures). Three 
lines of transgenic mice were selected for two generations 
of intercrossing with the nontransgenic GLK (+I-) mice 
to obtain all six possible combinations of transgene and 
knockout mutations. For the transgenic line, described in 
Table 3, all six combinations were born at close to the 
expected frequency. With the exception of the non- 
transgenic GLK (-I-) mice, there appears to be no in- 
crease in perinatal mortality. The genotype of the relevant 
mice (the status of the endogenous GLK locus and 
transgene presenceversus no transgene) was determined 
(A) The exonlintron structure of the mouse GLK is drawn using the 
known structure of the rat and human genes as guides. Not all mouse 
introns have been sequenced (Stoffel et al., 1992; Magnuson and 
Shelton, 1989). 
(B) Targeting construct consisting of Ex2-Ex3 and fx56-Ex70r PCR 
fragments, separated by the neo resistance gene. 
(C) GLK 8 cell transgene vector, constructed from human insulin pro- 
moter with the noncoding insulin exons 1 and 2(stippled boxes; Sarvet- 
nik et al., 1988) mouse 8 cell GLK cDNA (exons 18-10; boxes with 
vertical lines), and HBS terminator (hatched box; Sarvetnik et al., 
1988). 
(D and E) Mouse tail DNA PCR to confirm the presence of the GLK 
mutant allele by using primers 528-Neo7 (an expected size of 0.8 kb) 
(D) and using primers Ex5-ExlOi (an expected size of 5 kb) (E). Note 
that primer 528 (D) and primer ExlOi (E) are outside the targeting 
construct and that the sequence for primer Ex5 (see [A]) is deleted in 
the targeting construct. 
by polymerase chain reaction (PCR) analysis of genomic 
DNA taken from a tail biopsy using appropriate primers. 
GLK Activity in Liver and Islets of GLK Mutants 
Expression of the endogenous and transgenic GLK alleles 
in the liver and islets was determined by enzymatic and 
Northern blot hybridization analysis. GLK activity was re- 
duced in mice with only one functional allele, GLK (+I-) 
(Table 1). In the liver of GLK (+/-) mice, V,,, was reduced 
to 234 f 37 nmollmg protein per hour compared with 418 + 
42 nmollmg protein per hour in GLK (+/+) mice. In islets 
from GLK (+I-), V,,, is reduced by the same percentage 
as in the liver (3.0 mollkg DNA per hour versus 5.2 mall 
kg DNA per hour). Hexokinase activity was not obviously 
altered in either the liver or islets (data not shown). 
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Table 1, Kinetics of GLK in Liver and Islets of GLK (+I+) and GLK (+I-) Mice 
Liver Islet 
Measurement (+I+) (+I-) Percent of (+I+) (+I+) (+I-) Percent of (+I+) 
K, (GLK) (mM glucose) 9.4 * 0.1 8.1 f 0.5 87 12.5 f 10.7 10.0 f 8.2 80 
V,, (GLK) (nmollmg protein per hour) 417.5 f 41.9 233.8 k 37.3 56 
V,, (GLK) (mollkg DNA per hour) 5.2 f 1.8 3.0 k 2.3 57 
An mRNA species of approximately 2.4 kb was detected 
in the RNA from livers of wild-type animals and, at reduced 
intensity, in the heterozygotes. This mRNA was not detect- 
able in the transgenic homozygous mice (Figure 2A), and 
there was no detectable GLK activity in the livers of these 
mice (data not shown). A 4 kb mRNA, probably derived 
from the mutated allele, was detected in mice with at least 
one mutant GLK allele. This mRNA hybridized with both 
theGLKcDNAandwithaneoprobe(Figure2B).Additional 
smaller bands hybridizing to the neo probe were also de- 
tected (data not shown). These may have been derived 
by alternate splicing or termination of the transcript from 
the GLK mutant allele. 
That the transgene is expressed in the islets of the 
transgenic mice was demonstrated by reverse transcrip- 
tion PCR (RT-PCR). A fragment of the appropriate size 
(0.8 kb) was detected after analysis of the RNA from 
transgenic islets but not from nontransgenic islets (Figure 
2D). An additional product, which is detected in some 
transgenic islets, appears to be due to nonspecific hybrid- 
ization of the transgene-specific primer HBSr (see Figure 
1D) during PCR. 
E 
Figure 2. Expression of the GLK Transgene in Islets but Not in Liver 
(A) Northern blot analysis of liver mRNA from various mice of the 
indicated genotype, probed with GLK 6 cell cDNA. 
(B) Same blot as in (A) rehybridized with a neo probe. The bands 
shown are approximately 4 kb. 
(C) Same blot as in (A) probed with a GAPDH probe to determine the 
amount of loaded and transferred mRNA. 
(D) Southern blot of islet RT-PCR (ExlOf-HBSr, 0.8 kb; Figure 1C). 
The blot was probed with an oligo that is internal to the PCR fragment. 
(E) Aliquots of the islet cDNA used in (D) were used in a PCR with 
GAPDH primers to demonstrate that approximately equivalent 
amounts of RNA were used in (D) and to confirm the successful genera- 
tion of first-strand cDNA. 
A detailed analysis of the enzymatic activity provided 
by the different transgenes and the effects on glucose 
homeostasis is in progress. Preliminary analysis indicates 
that the level of GLK activity in the islets of the transgenic 
knockout mice described in this section is greater than 
that seen in the heterozygotes but less than the wild-type 
mice (data not shown). This transgenic line, in which the 
transgene is expressed in the islets but not in the liver, 
forms the basis for the results described below. 
Phenotypic Consequences of the GLK Mutation 
We investigated the effect of reduced GLK activity on 
blood glucose levels and whether this is modified by sex, 
age, mouse strain, or diet. Results are presented from the 
analysis of the GLKb line if not otherwise noted. The data 
obtained from mice in the GLKa line are not distinguish- 
able from the results obtained from the GLKb mice. 
At Pl , mice homozygous for the GLK mutation, GLK(-/-), 
have dramatically increased glucose values, 24.0 f 4.0 
m M  compared with 2.9 + 0.3 m M  in GLK (+I-) and 3.4 f 
0.2 m M  in GLK (+I+) mice (Table 2). These mice are 
slightly smaller from the day of birth (data not shown) and 
die by P3-P5. The heterozygotes also develop higher glu- 
cose levels from birth, although well below those seen in 
the GLK-deficient mice. The weight of the heterozygotes 
is not obviously different from the controls, and these mice 
develop normally and are fertile. 
Histological analysis revealed differences only in the 
livers of perinatal (P2 and older) GLK (-I-) mice (Figure 3). 
All other organs examined (brain, heart, intestine, kidney, 
lung, pancreas, skeletal muscle, spleen, stomach, and 
thymus) appeared to be normal, and by immunocytochem- 
istry there was no detectable difference in pancreatic insu- 
lin levels in neonatal GLK (+/+) and GLK (-I-) mice (data 
not shown). In the livers of perinatal GLK (-I-) mice, there 
is a significant reduction in liver glycogen stores (compare 
Figure 38 with Figure 3E), and an increase in vacuolization 
and lipid accumulation was observed as microvesicular 
steatosis (compare Figure 3C with Figure 3F). The hetero- 
zygotes appeared normal. That there are abnormalities in 
lipid metabolism is further indicated by an analysis of se- 
rum cholesterol and triglyceride levels (Tables 2 and 3). 
Both total cholesterol and triglycerides were elevated in 
the P3 GLK (-I-) mice, whereas only the triglycerides were 
significantly higher in the Pl GLK (-I-) mice. 
In adult GLK (+I-) mice (males and females), random 
(nonfasted) glucose values are significantly higher than 
those in GLK (+/+) mice (Table 3; p < 0.001). This increase 
in blood glucose values was observed from birth (see Ta- 
ble 2) through the test period of 8 months (Table 3; data not 
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Table 2. Glucose, Cholesterol, and Triglyceride Levels of Newborn Mice with GLK Deficiency 
Genotype 
Glucose (mM) 
Pl P2 P3 
Cholesterol (mgldl) Triglyceride (mgldl) 




3.4 f 0.2” 
p < 0.001 
2.9 zk 0.3” 
p < 0.001 
24.0 + 4.0b,C 
p < 0.001 
4.6 f 0.5a,b 
p < 0.001 
9.7 2 0.6”,’ 
p < 0.001 
23.3 +- l.Ob,c 
p < 0.001 
5.9 + 0.3a 
p < 0.001 
7.8 + 0.3a 
p < 0.001 
34.7 + 2.2b.C 
p < 0.001 
80.0 f 4.4a 
p < 0.001 
86.1 f 3.7” 
p < 0.001 
156 f llb.C 
p < 0.001 
297 k 38a 
p < 0.05 
264 f 22” 
p < 0.001 
481 -t 3w 
p < 0.001 b 
p < 0.05” 
237 + 20” 
p < 0.001 
246 f 27” 
p < 0.001 
789 k 94b,C 
p < 0.001 
Comparisons are not made among different ages; n = 6. Data were analyzed by two-way ANOVA. Group differences were evaluated with Fishers 
PLSD test. 
a p value is significantly different from that of (-I-) genotype. 
b p value is significantly different from that of (+/-) genotype. 
’ p value is significantly different from that of (+/+) genotype. 
shown). The diminished GLK activity in the heterozygotes 
also caused a comparable increase in the glucose levels 
(170% of wild type) in fasted mice (data not shown). 
As glucose levels in MODY patients appear to be sensi- 
tive to body mass index (Katagiri et al., 1992) we put a 
cohort of GLK (+I-) mice on a high fat diet at 4 weeks. 
The high fat diet caused a small increase in the weights 
of the mice (5.2 g in males and 2.1 g in females at 22 
weeks of age). While there was an effect of diet on the 
random glucose levels at 7 weeks of age, there was no 
obvious effect at 22 weeks, and there was no apparent 
effect on fasting glucose levels (data not shown). Both the 
C57BL16J and DBA/2J GLK (+I-) mice have comparable 
hyperglycemia in comparison with wild-type littermate 
controls (data not shown). Strain-dependent effects may 
become detectable with further backcrosses. 
The effect of the expression of the 6 cell-specific 
transgene on the glucose level depends on the status of 
the endogenous GLK genes. In wild-type mice, the trans- 
gene appears to lower the glucose levels slightly, but this 
effect was not statistically significant (Table 3). The trans- 
genie heterozygotes have glucose levels that are not sig- 
nificantly different from nontransgenic wild-type mice but 
that are significantly less than those measured in the non- 
transgenic heterozygotes. In the homozygous knockout 
mice, the transgene provided the difference between sur- 
vival and perinatal death. These transgenic homozygous 
mice had glucose levels that were 12.9 f 1.5 mM as 
compared with 6.3 f 0.5 mM in the transgenic heterozy- 
gotes and 10.4 f 0.4 mM in heterozygous mice. Although 
the mean glucose levels in the transgenic homozygous 
mice are clearly higher than those measured in the wild- 
type mice, approximately 50% of these mice have random 
glucose levels that are consistently within the normal 
range. 
The transgenic knockout mice have moderately ele- 
vated glucose levels but are otherwise healthy and are 
fertile. The histologically obvious pathology that appears 
in the P3 knockout mice is also to a large extent reversed 
(data not shown). More detailed analysis may reveal more 
subtle structural or metabolic differences. 
To define further the impact of altered GLK expression 
on glucose homeostasis, we performed glucose challenge 
studies. In comparison with wild-type mice, the heterozy- 
Figure 3. Liver Sections of P3 GLK (-/-) and 
GLK (+I+) Mice 
(A) Hematoxylin and eosin stain. 
(B) PAS stain demonstrating glycogen levels. 
(C) Oil red 0 stain demonstrating lipid levels 
of a liver section from a P3 GLK (-I-) mouse. 
(D) Hematoxylin and eosin stain. 
(E) PAS stain demonstrating glycogen levels. 
(F) Oil red 0 stain demonstrating lipid levels of 
P3 GLK (+I+) mice. 
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6.2 f 0.2",b 
p < 0.001 
10.4 f 0.4b.c.d.e 
p < o.oolc~~~~ 
p < 0.05b 
4.9 + 0.3=,h 
p < 0.001 
6.3 f 0.5@ 
p < 0.001 
12.9 f lSC,d,’ 
p < 0.001~~~~ 
p < 0.05” 
Cholesterol (mgldl) Triglyceride (mgldl) 
125 f 10.3 143 k 37.5 
118 k 5.4 147 f 14.1 
142 zk 18.1 127 f 29.3 
117 f 8.9 140 f 21.5 
123 f 4.5 149 k 24.6 
Comparisons are not made among different ages: n = 6, except for glucose levels, where n = 32. Data were analyzed by two-way ANOVA. Group 
differences were evaluated with Fisher’s PLSD test. 
a p value is significantly different from that of (+I-) genotype. 
b p value is significantly different from that of transgenic (-I-) genotype. 
c p value is significantly different from that of (+/+) genotype. 
d p value is significantly different from that of transgenic (+I+) genotype. 
* p value is significantly different from that of transgenic (+I-) genotype. 
gotes have an impaired ability to dispose of injected glu- 
cose, whereas in the transgenic heterozygotes, the mean 
glucose levels were not distinguishable from the wild-type 
mice (Figure 4A). In the transgenic knockout mice, the 
mean glucose levels were significantly higher than in any 
of the other groups (Figure 4A). There is more variation in 
the glucose values obtained with the transgenic knockouts 
thaninanyothergroupsandslightlymorein thetransgenic 
heterozygotes than in the nontransgenic heterozygotes. 
This variation becomes more obvious when the curves for 
0 40 80 120 160 0 40 80 120 160 
Time (mln) 
Figure 4. Glucose Challenge of Mice with Different GLK Phenotypes 
(A) Presented are the mean (r SEM) blood glucose values from 16 
hr fasted GLK (+/+) (squares; n = 6) GLK (+I-) (circles; n = 6) 
transgenic GLK (+I-) (triangles; n = 5), and transgenic GLK (-I-) 
(diamonds: n = 6) male mice after injection with 1 g of glucose per 
kilogram of body weight. 
(13) Comparison of the average blood glucose levels from GLK (+/+) 
(squares; n = 6) mice with five individual transgenic GLK (+I-) (trian- 
gles) mice affer a glucose challenge. 
(C) Blood glucose values of six individual transgenic GLK (-I-) mice 
(diamonds) in comparison with the average glucose of GLK (+/+) mice 
(squares; n = 6) after a glucose challenge. 
the individual mice are plotted (Figure 48). These individ- 
ual curves reveal responses that range from diabetic (a 
1 hr value of greater than 11 mM) to several mice that 
returned to the initial values considerably faster than nor- 
mal. Comparable curves are given in Figure 4C for the 
transgenic knockouts. Within this group there also appear 
to be several discrete phenotypes. From both an analysis 
of the numbers of transgenic animals born and gene struc- 
ture analysis, there is no evidence to support the possibility 
that this variability derives from there being independently 
segregating transgenes with different levels of expression 
(data not shown). Furthermore, for individual mice, the 
glucose disposal curves were not significantly different 
when retested 2 months later. 
Impact of the GLK Mutation on Insulin Levels 
and insulin Secretion 
Although the GLK (+/-) mice have higher glucose levels 
than the wild-type mice, the nonfasting insulin levels were 
not significantly different (data not shown). The difficulty 
in interpreting insulin levels in mice with different glucose 
values was overcome by using an organ perfusion ap- 
proach (Figure 5). Pancreata from GLK (+/-) mice have 
no recognizable first-phase response while perfused with 
5 mM glucose. Increasing glucose to 11 mM resulted in 
a low first-phase response (1.5 nglml versus 7 nglml in 
wild type). The second-phase response was marginally 
above the 0 mM baseline. Stimulation with 22 mM glucose 
doubled the first-phase response compared with the 11 
mM stimulation (3 rig/ml versus 10 nglml for wild type), 
while the second-phase remained low (2 rig/ml versus 8 
nglml in wild type). A detailed analysis of insulin secretion 
in comparison with the level of GLK expression in mice with 
the other combinations of GLK alleles (transgenic versus 
nontransgenic and heterozygotes versus knockouts) is in 
progress and will be published elsewhere. 
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Figure 5. Insulin Secretion of Perfused Pancreata from GLK (+/+) and 
GLK (+I-) Mice 
Average insulin secretion of perfused pancreata of GLK (+I+) (thick 
line; n = 4) and GLK (+I-) (thin line; n = 4) mice. Pancreata were 
perfused with a stepwise increase in glucose starting from 0 mM glu- 
cose (l-20) 5 mM glucose (21-40) and 11 mM glucose (41-60) to 
22 mM glucose (61-80). The values represent the mean ? SEM of 
the four mice in each category with the insulin values for each mouse 
in each fraction determined in duplicate. 
Discussion 
GLK (+I-) Mice Are Hyperglycemic 
Mice that have only one normal GLK allele express lower 
levels of functional GLK protein, have an impaired f3 cell 
response to glucose, and are hyperglycemic. Two lines 
of GLK-deficient mice generated from independent clones 
of targeted ES cells have comparable hyperglycemia, sup- 
porting the conclusion that the phenotypic changes are 
due to the mutation in the GLK gene rather than to a sepa- 
rate but tightly linked mutation that arose in the ES cells. 
The insulin levels in these hyperglycemic GLK-deficient 
mice are not significantly different from their normogly- 
cemic littermates. This decreased insulin/glucose ratio 
suggests an increase in insulin sensitivity. The insulin lev- 
els in hyperglycemic MODY patients are also not signifi- 
cantly different from the controls (Katagiri et al., 1992; 
Byrne et al., 1994). 
GLK Compensation 
The reduction in the level of GLK activity in those mice 
with only one functional allele implies an inadequate regu- 
lation of GLK expression to compensate for the loss of 
one allele. Regulation of GLK expression is complex (re- 
viewed by Magnuson, 1992). There are two independent 
tissue-specific promoters and first exons. The 5’promoter 
and first exon are used in f3 cells, and the more 3’promoter 
and first and second exons are used in the liver. GLK 
activity in the liver appears to be primarily controlled by 
insulin-mediated regulation of transcription (Magnuson et 
al., 1989), whereas in p cells, GLK activity may be con- 
trolled by glucose through increased translation or re- 
duced degradation of the enzyme (lynedjian et al., 1989; 
Liang et al., 1992) or directly on GLK activity (Chen et al., 
1994). If insulin is the primary mediator of GLK levels in 
the liver, then the lack of compensation in this organ could 
be explained by the observation that heterozygous mice 
have insulin levels comparable to the wild-type mice. In 
b cells, GLK activity appears to be positively regulated 
by glucose, and the metabolism of glucose is positively 
regulated by the level of GLK activity. This suggests the 
presence of a self-reinforcing feedback loop inside the p 
cell counterbalanced by a negative feedback loop acting 
through glucose-stimulated insulin secretion. Thus, it is 
possible that a reduction in GLK activity (by, for example, 
the loss of one allele) would also reduce the ability of the 
f3 cell to recognize the decrease. Although there seems 
to be little compensation in these mice for the loss of one 
GLK allele, in at least some patients with MODY, there 
does appear to be a mechanism that partially compen- 
sates (Sturis et al., 1994). 
Insulin Secretion 
Heterozygotes with their GLK activity reduced (57%) have 
an impaired ability to secrete insulin in response to an 
increase in glucose. In spite of this impairment, these het- 
erozygotes have circulating insulin levels comparable to 
the wild-type mice. This result is expected from the combi- 
nation of the decreased sensitivity of the pancreata to glu- 
cose and the increase in circulating glucose. At 11 m M  
glucose, the heterozygous pancreas will release approxi- 
mately the same amount of insulin as is released by the 
wild-type pancreas stimulated by the physiological con- 
centration of 5 m M  (Figure 5). These glucose concentra- 
tions (5 m M  in the wild-type mice and 11 m M  in the hetero- 
zygotes) are close to those present in the circulation of 
these animals (Table 3). Comparable considerations can 
be made with respect to the glucose concentration re- 
quired in the heterozygotes to match the GLK velocity in 
the wild-type mice at 5 m M  glucose (see Table 1). These 
results are consistent with the possibility that the level of 
GLK activity is responsible for the glucose setpoint as well 
as acting as the glucose sensor. When the starting glucose 
concentrations are normalized, insulin secretion rates in 
MODY patients are also significantly less than in controls 
(Byrne et al., 1994). 
A reduction in (j cell GLK has been obtained using an 
antisense transgene approach (Efrat et al., 1994). This led 
to a reduced sensitivity of the p cells to glucose, but there 
was no alteration in circulating glucose levels. An increase 
in f3 cell hexokinase levels has been achieved in both iso- 
lated islets and in transgenic mice (Becker et al., 1994; 
Voss-McGowan et al., 1994). Although a significant in- 
crease in the level of hexokinase expression (5 to 8-fold) 
was obtained, the subsequent increase in glucose utiliza- 
tion and insulin secretory response to glucose was less 
(8fold). It was suggested that this may have been a conse- 
quence of other components of the 0 cell response becom- 
ing rate limiting at the high hexokinase levels that were 
obtained. 
Although not directly determined through pancreas per- 
fusion, the marked hyperglycemia in the GLK (-/-) mice 
suggests that insulin secretion is even more impaired in 
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these mice. Insulin release in these mice may be induced 
by glucose metabolism through hexokinase in combina- 
tion with stimuli from amino acids, fatty acids, glucagon, 
and other compounds. 
Consequences of Complete GLK Deficiency 
Mice that are completely deficient in GLK are born at the 
expected frequency with no obvious pathological lesions 
in the major organs. They are, however, markedly hyper- 
glycemic, and there are histological changes in the liver 
that become apparent by P2. These liver changes include 
microvesicular steatosis and a depletion of glycogen. In 
addition, there is an increase in circulating triglycerides. 
An increase in liver uptake of lipids subsequent to this 
hypertriglyceridemia may be responsible for the hepatic 
steatosis. The alternative of an increase in hepatic lipid 
synthesis is less likely given the relative decrease in insulin 
secretion in these mice. Liver glycogen is decreased in 
the homozygotes. Glycogen is derived from circulating 
glucose (after phosphorylation by GLK) or from gluconeo- 
genesis. As glycogen synthesis is stimulated and glycoge- 
nolysis is inhibited by insulin, the relative reduction in insu- 
lin that occurs in the GLK-deficient mice should lead 
directly to a loss of liver glycogen. The marked imbalance 
between glucose-6-phosphatase and GLK that is present 
in the livers of these mice may mean that an additional 
control point, the direct inhibitory effect of glucose on gly- 
cogenolysis, may be missing (Rossetti et al., 1993). 
The complete loss of GLK is fatal, usually by P5. As the 
mice are markedly hyperglycemic from birth (22-33 mM), 
it is possible that they die from coma caused by hyperos- 
molality. 
Transgenic Rescue of GLK-Deficient Mice 
It is not known whether the diabetes in patients with MODY 
is caused by a deficiency in f3 cell GLK or hepatic GLK 
(or both). To separate out the effects of 6 cell versus liver 
GLK deficiency, we have generated transgenic mice in 
which a mouse 6 cell GLK cDNA is expressed from the 
human insulin promoter. 
The 6 cell GLK transgene has a marked effect on GLK 
(-I-) mice: the transgenic mice survive, whereas the non- 
transgenic GLK (-I-) mice die perinatally with extreme 
hyperglycemia. The presence of p cell GLK in the complete 
absence of liver GLK is sufficient to completely normalize 
some (cholesterol and triglycerides [Tables 2 and 31, as 
well as blood urea nitrogen, albumin, and total protein 
[data not shown]), but not all (fasting and fed glucose; 
Tables 2 and 3; Figure 4C) abnormalities that were de- 
tected in the P3 GLK-deficient mice. Although the mean 
glucose levels (random and following an intraperitoneal 
glucose tolerance test) are higher in the transgenic homo- 
zygous mice than in the wild-type mice, approximately 
50% of these transgenic homozygous mice have glucose 
levels that are indistinguishable from wild-type mice. The 
glucose control in the heterozygous mice is clearly abnor- 
mal, whereas the transgenic heterozygotes have mean 
fed and fasting glucose levels that are not distinguishable 
from wild-type mice, and the mean glucose profiles follow- 
ing an injection of glucose also appear normal. 
Thus, provided that 6 cell GLK levels are sufficient, it 
is possible to maintain normoglycemia in the presence of 
only one functional GLK allele in the liver. Even in the 
complete absence of liver GLK, it is possible to maintain 
glucose levels that are near normal or, in some cases, 
indistinguishable from normal. 
Heterogeneity between Individual Mice 
Mice with the same genotype with respect to either the 
endogenous GLK gene or the GLK transgene can have 
markedly different fed and fasted glucose levels and re- 
sponses to injected glucose. This increased variability is 
obvious in both the variability in the mean glucose levels 
(Table 3) and in the glucose challenge studies (Figure 4A). 
The increased variation that is apparent in comparisons 
between wild-type and heterozygous mice is also seen in 
comparisons between the transgenic and the nontrans- 
genie mice. 
Following the cross that generated the transgenic 
knockout mice, there are segregating alleles derived from 
the 129/Sv, C57BL/6J, and SJUJ mouse strains. It may 
be that the phenotypic heterogeneity is derived from this 
genetic heterogeneity. This genetic heterogeneity ap- 
pears to have an effect in those mice with decreased ex- 
pression or an altered pattern of expression of GLK but 
little impact in the context of normal GLK expression. Inter- 
crossing of mice with selected glucose-related pheno- 
types is in progress to examine this. It has been noted 
that within MODY families with the same GLK mutation, 
some family members will be diabetic whereas others will 
be more modestly affected with either glucose intolerance 
or mild fasting hyperglycemia (Hattersleyet al., 1992; Fro- 
guel et al., 1993) and these differences may be exagger- 
ated by changes in the body mass index (Katagiri et al., 
1992). 
Hepatic Glucose Output 
In individuals with diabetes, an increase in gluconeogene- 
sis and hepatic glucose output (HGO) is primarily responsi- 
ble for the fasting hyperglycemia. The level of HGO ap- 
pears to be primarily controlled by the relative rates of 
glucose phosphorylation by GLK and dephosphorylation 
by glucose-6-phosphatase (reviewed by Davis and Pagli- 
assotti, 1994). Theobservation that the heterozygous mice 
have diminished liver GLK activity and have an increase 
in fasting glucose is consistent with there being an in- 
crease in HGO in these mice. The availability of mice that 
have reduced hepatic GLK in the presence of near-normal 
levels of glucose, insulin, and 6 cell GLK will provide an 
opportunity to evaluate directly the role of hepatic glucose 
phosphorylation in the regulation of HGO. 
GLK in NIDDM 
The possibility that alterations in GLK expression are in- 
volved in the more common forms of NIDDM has been 
investigated. Although there have been reports of positive 
genetic associations in selected racial groups (Chiu et al., 
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1992a, 1992b; Elbein et al., 1993; Noda et al., 1993; Mc- 
Carthy et al., 1993), in others there has been no associa- 
tion (Tanizawa et al., 1993). Furthermore, family studies 
have in general failed to demonstrate linkage or GLK muta- 
tions even in those situations in which there was associa- 
tion (McCarthy et al., 1993; Elbein et al., 1993; Chiu et 
al., 1993). In a separate report, two individuals (of 40 
screened), with both gestational diabetes and a relative 
with NIDDM, had mutations in one of their GLK alleles 
(Stoffel et al., 1993) and in one group of obese NIDDM 
patients, there was a significant decrease (50%) in hepatic 
GLK activity in comparison with either lean or obese nondi- 
abetic individuals (Caro et al., 1995). Although it appears 
that mutations in the GLK gene are relatively rare in the 
more common forms of NIDDM, it is possible that geneti- 
cally determined alterations in other proteins (for example, 
the GLK regulatory protein or transcription factors) could 
indirectly couple GLK to the development of NIDDM. 
Conclusion 
Mice that have one functional GLK allele have a dimin- 
ished b cell response to glucose and are hyperglycemic, 
whereas mice that completely lack GLK are markedly dia- 
betic at birth and die, usually by P5. Mice that express 
GLK exclusively in the f3 cells survive and have glucose 
levels that range from normal to moderately diabetic. 
These transgenic knockout mice point to b ceil GLK having 
a greater impact on glucose homeostasis than liver GLK 
and provide strong support for the concept that GLK is 
the primary b cell glucose sensor. 
Experimental Procedures 
Construction of Replacement and Transgene Vectors 
The GLK replacement vector (pRKTK.GLK) was generated in several 
steps. A 0.6 kb 5’ genomic and a 4.5 kb more 3’ genomic GLK DNA 
fragment was isolated from purified mouse ABl ES cell DNA by PCR. 
The primers used for these PCRs were located in exon 2 (fx2) and 
exon 3 (Ex3) and in exon 5 (fx5b) and exon 10 (ExlOr), respectively. 
The sequences of these and all other oligonucleotides are available 
on request. The two PCR products were subcloned such that the fx2- 
Ex3 fragment is flanked on the 5’ side by the herpes simplex virus 
thymidine kinase gene under the control of the CMV promoter, and 
the two genomic fragments are separated by the neo resistance gene 
under the control of the PGK promoter. The PGK-neo gene is in the 
same transcriptional orientation as the GLK gene. 
To construct the transgene, we amplified the GLK cDNA by RT- 
PCR from C57BU6J islet RNA with the E76-2 and the ExlOioligonucle- 
otides as PCR primers. The PCR fragment was subcloned, completely 
sequenced in both directions, and inserted into plnspro (Sarvetnik et 
al., 1968) to generate plNS.GLK.HBS. 
Generation of Knockout Mice 
ABI ES cells (passages 1 l-1 3) were grown on mitomycin C-treated 
G418-resistant ST0 cell feeder layers (Robertson, 1987) in DMEM 
containing 10% fetal bovine serum and 0.1 mM 6-mercaptoethanol 
at 37% and 5% CO*. The ES cells were electroporated (4 x lo5 cells 
in 0.4 ml of PBS and 16 ug of Notl-linearized pRKTK.GLK DNA) in a 
0.4 cm cuvette of a Bio-Rad Genepulser set at 230 V, 500 uF, and 
600 ohms. Electroporated cells were plated, and G418 (ZOO uglml 
effective concentration; Sigma) and gancyclovir (2 PM) were added 
48 hr later. Surviving clones were picked into 96-well plates coated 
with feeder ST0 fibroblasts and expanded for DNA isolation. DNA 
from the cells was analyzed for homologous recombination by PCR 
with a GLK forward primer that was outside the targeting vector (primer 
528) located in Ex2 of the GLK gene and with a reverse primer, Neal, 
located in the neo resistance gene. Cells that had undergone homolo- 
gous recombination gave a diagnostic 0.8 kb PCR fragment. Positive 
results were confirmed by Southern blot analysis. 
We used three cell clones that were positive for homologous recom- 
bination for microinjections into the blastocoel cavity of P3.5 C57BU 
6J blastocysts (Hogan et al., 1986). Agouti-colored male mice derived 
from these injected blastocysts were test bred with C57BU6 females 
and their agouti offspring screened for germline transmission by tail 
DNA PCR with primers 528 and Neal. All subsequent offspring were 
analyzed by tail DNA PCR. 
Generation of Transgenic Mice 
A 4.6 kb Asel restriction fragment was isolated from plNS.GLK.HBS 
and used for injection into i-cell stage (SJL x C57BU6J) x (SJL x 
C57BU6J) embryos (Sarvetnick et al., 1988). Transgenic mice were 
identified by Southern blot analyses of DNA extracted from the tails. 
Subsequently transgenic mice were identified by PCR from tail DNA 
with Ex5 and Ex6r PCR primers, yielding a 0.18 kb band for the 
transgene and a 0.3 kb band for the wild-type allele. 
To generate transgenic knockout mice, GLK (+I-) mice were bred 
to transgenic GLK mice. Resulting transgenic GLK (+I-) mice were 
intercrossed to GLK (+/-) mice to generate transgenic GLK (+I+) mice. 
Genotyping was performed by tail DNA PCR with primer sets 528- 
Neal (mutant allele) and Ex5-Ex6r (wild-type allele and transgene, 
respectively; note that the sequence for Ex.5 is deleted in the mutant 
allele). 
Northern Blots 
Total RNA was isolated from islets or liver with RNA STAT-60 (TEL- 
TEST 6, Incorporated). To purify poly (A)+ RNA, we used the polyA- 
Tract mRNA isolation system (Promega). Poly(A)‘(2 ug) mRNA or total 
RNA (20 ug) was loaded on a 0.9% agarose, 6% formaldehyde gel, 
electrophoresed, transferred to a nitrocellulose membrane, and hy- 
bridized to the GLK cDNA fragment. 
Analytical Procedures 
Blood glucose values were determined from whole venous blood by 
using an automatic glucose monitor (One Touch II, Lifescan). Insulin 
levels were measured by RIA (rat insulin RIA kit, Linco) from portal 
vein blood. Cholesterol and triglyceride analyses were performed from 
serum samples on a Hitachi analyzer. 
Glucose Challenge 
Overnight fasted mice were injected intraperitoneal with 1 g of glucose 
per kilogram of body weight. Blood glucose values were measured 
immediately before and 10, 20, 30, 60, 120, and 180 min after the 
injection. 
Hexokinase and GLK Assays 
Glucose phosphorylating activity was analyzed either from freshly pre- 
pared mouse islets (>400) or liver by a fluorometric assay measuring 
NADH formation. The methods are described by Trus et al. (1981) and 
Liang et al. (1991). In brief, islets were washed free of glucose and 
homogenized (20 mM &HP04, 5 mM DTT, 1 mM EDTA, 110 mM KCI) 
on ice. An aliquot was taken to determine DNA content (Labarca and 
Paigen, 1980). Homogenized islets were centrifuged for 10 min at 
12,000 x g to remove mitochondrial bound hexokinases. We added 
5 ul of supernatant to 100 ul of reaction buffer (50 mM HEPES [pH 
7.61, 100 mM KCI, 15 mM 6-mercaptoethanol, 7.4 mM MgC&, 0.5 mM 
NAD’, 5 mM ATP, 0.05% BSA, 0.7 U/ml glucose-6-phosphate dehy- 
drogenase from Leuconostoc mesenteroides) and incubated the mix- 
ture with varying glucose concentrations (0, 0.03, 0.06, 0.125, 0.25, 
0.5, 6, 12, 24, 60, and 100 mM) for 90 min at 30%. The reaction was 
stopped by addition of 2 ml of 0.5 M  NaHC03 (pH 9.4). Glucose-B- 
phosphate standardsand reagent blanks wereincluded. Each reaction 
was performed in triplicate. NADH formation was measured fluoromet- 
rically (350 or 460 nm). K, and V,,, values were calculated from Eadie- 
Scatchard plots including an additional correction method according 
to Spears et al. (1971) with 10 correction cycles. Liver hexokinase and 
GLK were assayed in the same way with the exception that homoge- 
nized liver extracts were centrifuged at 100,000 x g at 4’C for 70 
min. Of the supernatant (about 5 mg of wet liver weight per milliliter 
of supernatant), 5 pl was used for the above assay. Kinetic data for liver 
samples were calculated according to total protein amount (Bio-Rad). 
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In Vitro Pancreas Perfusion 
The pancreata with adjacent duodenum were surgically removed from 
pentobarbital-anesthetized fed mice (100 mg/kg body weight) and per- 
fused as previously described (Ma et al., 1994). In brief, perfusate 
consisting of bicarbonate-phosphate-calcium buffer with 0.2% puri- 
fied stabilized BSA and 3% Dextran T-40 was introduced into the celiac 
artery at 0.9 ml/min. Effluent was collected at 1 min intervals from the 
portal vein after single passage through the tissue, and the insulin 
secreted was assayed. At the end of each experiment, pancreatic 
insulin content was determined by extracting insulin from homoge- 
nized pancreata in acid-alcohol (alcohol:H20:concentrated HCI at a 
ratio of 750:235:12). 
Histological Analyses 
A portion of removed organs was fixed in neutral buffered formalin, 
embedded in paraffin, then sectioned, and stained with hematoxylin 
and eosin. Sections of liver were stained by periodic acid-Schiff re- 
agent (PAS) with and without diastase digestion to demonstrate glyco- 
gen. Pancreas was stained for insulin by immunoperoxidase. Liver 
cryosections were stained for lipid by oil red 0. 
Statistical Analyses 
Each variable was analyzed by a two-way analysis of variance 
(ANOVA). We used Fisher’s protected least significant difference 
(PLSD) test (p < 0.05) to evaluate group differences. For all analyses, 
a p value of less than 0.05 was considered significant. Results are 
given as means r 1 SEM. 
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